---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-009399"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T05:23:29.116833+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCardia reports FY2024 net loss $7.9M, cash $2.4M; CardiAMP HF data to be presented at ACC March 30

## Summary
- Net loss $7.9M vs $11.6M in 2023; net cash used in ops $8.0M vs $10.0M.
- Revenue $58K vs $477K; R&D expense $4.4M (down from $7.7M); SG&A $3.7M (down from $4.4M).
- CardiAMP HF trial results to be presented at ACC Late-Breaking Clinical Trials on March 30, 2025; data intended for FDA/PMDA registration.
- Completed low-dose cohort of CardiALLO (BCDA-03); DSMB review Q2 2025. First commercial Morph DNA steerable introducers available.
- Cash and cash equivalents $2.4M at year-end 2024.

## SEC filing metadata
- accession: 0001437749-25-009399
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925009399/0001437749-25-009399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925009399/bcda20250326_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-009399
- JSON: https://secwatch.observer/filing/0001437749-25-009399.json
- Plain text: https://secwatch.observer/filing/0001437749-25-009399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.